Novo Nordisk's shares increased by 7 % after the latest remedy for weight loss manufacturer has shown a promising




The new treatment focuses on the GLP-1 intestinal hormone, but also mimics amylin, the hormone released by the pancreas that suppresses hunger. Read more

Leave a Reply

Your email address will not be published. Required fields are marked *